Lower sales of Tysabri predicted

Boston Globe, August 6, 2008

It is expected that fewer patients will be taking Tysabri, used to treat multiple sclerosis, as two more patients have been diagnosed with a potentially fatal brain disease. Financial analysts predict that the drug will have only about 75,000 users by 2013, which is below Biogen Idec Inc.'s goal of 100,000.


MOST POPULAR

SPONSORED REPORTS
SPONSORED HEADLINES

SIGN UP

FREE e-Newsletters Join the Council Subscribe to HL magazine

SPONSORSHIP & ADVERTISING

100 Winners Circle Suite 300
Brentwood, TN 37027

800-727-5257

About | Advertise | Terms of Use | Privacy Policy | Reprints/Permissions | Contact
© HealthLeaders Media 2015 a division of BLR All rights reserved.